Scrip 100: Genentech leads new breast cancer class with Seragon acquisition
This article was originally published in Scrip
Executive Summary
Genentech has a leading position in HER2-positive breast cancer, so it made sense for the Roche-owned company to plant its flag in a second, larger part of the breast market with an initial investment of $725m to buy San Diego-based Seragon Pharmaceuticals in July this year.